Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Nexobrid® (anacaulase-bcdb) – Expanded indication
August 15, 2024 - Vericel Corporation announced the FDA approval of Nexobrid (anacaulase-bcdb), for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.